Picture loading failed.

Anti-EGFR;MET therapeutic antibody (Pre-made Amivantamab biosimilar,Bispecific mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Amivantamab, sold under the brand name Rybrevant, is a monoclonal antibody medication used to treat non-small cell lung cancer.

Order informatioin


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-021-1mg 1mg 3090
GMP-Bios-ab-021-10mg 10mg 21890
GMP-Bios-ab-021-100mg 100mg 148000
GMP-Bios-ab-021-xmg ≥100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Anti-EGFR;MET therapeutic antibody (Pre-made Amivantamab biosimilar,Bispecific mAb)
INN Name Amivantamab
TargetEGFR;MET
FormatBispecific mAb
DerivationBispecific antibody
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa;Kappa
Highest_Clin_Trial (Jan '20)Preregistration
Est. StatusActive
100% SI StructureNone;6wvz:HL
99% SI StructureNone;None
95-98% SI StructureNone;None
Year Proposed2019
Year Recommended2020
CompaniesGenmab;Janssen Research & Development
Conditions Approvedna
Conditions ActiveNon-small cell lung cancer;Solid tumours
Conditions Discontinuedna
Development Techna